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Mechanisms of minocycline resistance
Minocycline clinical effectiveness
A B S T R A C T
Objectives: The increasing crisis regarding multidrug-resistant (MDR) and extensively drug-resistant
microorganisms leads to appealing therapeutic options.
Methods: During the last 30 years, minocycline, a wide-spectrum antimicrobial agent, has been effective
against MDR Gram-positive and Gram-negative bacterial infections. As with other tetracyclines, the
mechanism of action of minocycline involves attaching to the bacterial 30S ribosomal subunit and
preventing protein synthesis.
Results: This antimicrobial agent has been approved for the treatment of acne vulgaris, some sexually
transmitted diseases and rheumatoid arthritis. Although many reports have been published, there
remains limited information regarding the prevalence, mechanism of resistance and clinical
effectiveness of minocycline.
Conclusion: Thus, we summarize here the currently available data concerning pharmacokinetics and
pharmacodynamics, mechanism of action and resistance, antibacterial activity and clinical effectiveness
of minocycline.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Minocycline is a highly lipophilic molecule, second-generation
and semisynthetic tetracycline analogue [1]. It can effectively cross
the blood–brain barrier and impedes various Gram-positive and
Gram-negative bacteria [2]. It was first introduced in the 1960s. Its
primary mechanism of action for antimicrobial activity is based on
the fact that tetracyclines attach to the bacterial 30S ribosomal
subunit and prevent protein synthesis [3]. Minocycline has more
tissue absorption intothe cerebrospinal fluidand the central nervous
system (CNS) and a longer half-life in comparison with first-
generation tetracyclines [2]. Modification in ring D through carbons
7–9 is the basis for the higher efficacy of minocycline [4]. It has been
mainly approved and used for the treatment of some sexually
transmitted diseases and rheumatoid arthritis by the US Food and
Drug Administration (FDA) [5,6]. When minocycline is orally
administered, there is quick and excellent absorption and tissue
penetration, longer half-life and potent bioavailability; thus, it has a
superior pharmacokinetic profile compared with first-generation
tetracyclines [7–10]. Currently, most reports have focused on the
non-antibiotic properties of minocycline. We summarize the
currently available data concerning pharmacokinetics and pharma-
codynamics, mechanism of action and resistance, antibacterial
activity and clinical effectiveness of minocycline.
2. Structural characterization
Minocycline (7-dimethylamino-6-dimethyl-6-deoxytetracy-
cline) is named chemically as (4S,4aS,5aR,12aR)-4,7-bis(dimethy-
lamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahy-
dro-4H-tetracene-2-carboxamide [11]. Its chemical formula isFig. 1. The chemical structure of minC23H27N3O7 and its molecular weight is 457.5 g/mol. Minocycline
is a tetracycline containing a dimethylamino group at position 7
without methyl and hydroxy groups at position 5; therefore, it
shows more lipophilicity than other tetracyclines, with optimal
tissue penetration [9,12,13]. Fig. 1 shows the chemical structure of
minocycline and other tetracyclines.
3. Pharmacokinetics and pharmacodynamics
Preliminary studies of intravenous (i.v.) minocycline pharma-
cokinetics have showed a desired serum concentration (Cmax = 3–
8.75 mg/mL) compared with other tetracyclines. Minocycline is
mainly expelled via the faeces and at a low rate via the urine (5–
12%) [14]. Minocycline is metabolized by the liver [9,12]. The
excretion half-life of minocycline ranges from 15 to 23 h, which is
the same as doxycycline, but significantly longer than that of the
first tetracycline [15]. However, similar to tetracycline, minocy-
cline’s protein-binding capacity is 76% [9]. Minocycline’s circula-
tion volume ranges from 67.5 to 115 L [9,12]. The tissue to plasma
ratio in the liver, gallbladder and bile fluids, prostate and
genitourinary organs is >1.0. In addition, the tissue serum
concentration ratio is 3.80 in the lung [9]. Human and animal
model studies have demonstrated that the cerebrospinal fluid
(CSF) penetration of minocycline is insignificant (>50% of serum
concentrations) [7,8,12,16,17]. Kidney failure and liver cirrhosis
have a slight effect on the half-life and area under the
concentration-time curve (AUC) of minocycline, however, careful
administration is recommended for these patients [9,18]. The oral
administration of minocycline has a more suitable pharmacoki-
netic profile than the earliest tetracycline [19].ocycline and other tetracyclines.
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It has been indicated that minocycline has side effects in
patients [20]. Frequent minocycline adverse effects include
gastrointestinal symptoms (e.g. nausea, diarrhoea, flatulence,
vomiting), vestibular disturbance (dizziness) and cutaneous
symptoms (e.g. hyperpigmentation of skin and mucous mem-
branes, pruritis, urticaria and photosensitive rash) [20,21].
Appropriate clinical monitoring is recommended for long-term
treatment with minocycline [22]. Hyperpigmentation is a
frequent adverse effect in patients on long-term minocycline
therapy in a range of organs, including the skin, teeth, bone,
thyroid and sclera [20,21,23–28]. However, the hyperpigmenta-
tion process is reversible; the nature of minocycline-induced
cutaneous hyperpigmentation is mostly cosmetic and not
associated with adverse clinical effects [25,29]. The proposed
predisposing factors for hyperpigmentation, still uncertain, in
patients include higher doses [20] and aging [30]. However, in
most cases, the hyperpigmentation process is reversible, and the
pigmentation fades after minocycline cessation [31]. In a
systematic review [32] on the adverse effects of doxycycline
and minocycline, no divergence was shown in gastrointestinal
complaints. Minocycline had a larger adverse effect of CNS
symptoms, such as vertigo. For the most part, three serious but
infrequent side effects include dose-related toxicity reactions
with early onset resulting in single-organ dysfunction, hypersen-
sitivity syndrome (pneumonitis, eosinophilia, hepatitis, pancrea-
titis, nephritis and serum sickness-like syndrome), and
autoimmune disorders (drug-induced lupus erythematosus-like
eruption, autoimmune hepatitis and polyarteritis nodosa) [21,33].
Another serious minocycline-related side effect is anaphylaxis (a
life-threatening reaction to drugs) that was reported in a 56-year-
old woman after receiving oral minocycline [21]. Vasculitis
neuropathy following exposure to minocycline has also been
reported [34]. A Cochrane review has proposed that it should no
longer be used as first-line therapy, partly owing to the indefinite
risk of adverse effects [33,35,36].Fig. 2. Minocycline mechanism5. Characteristics of minocycline
5.1. Mechanism of action
The main mechanism of action in minocycline is similar to the
other tetracycline drug family [37]. Tigecycline acts as an inhibitor
of bacterial protein translation (elongation of the peptide chain)
via binding reversibly to a helical region (H34) on the 30S subunit
of bacterial ribosomes; this blocks the incorporation of amino acid
residues into the elongating peptide chains, resulting in the loss of
peptide formation and bacterial growth [10,37] (Fig. 2).
5.2. Mechanisms of resistance
A variety of mechanisms, including the efflux pump and
modification or protection of the antibiotic target sites are involved
in resistance to tetracyclines. The tet efflux genes code for
membrane-related proteins that flow tetracyclines out of bacteria,
and lead to minimum inhibitory concentration (MIC) reduction of
the drug intracellularly, consequently protecting the ribosomes.
The Tet proteins, such as Tet(B), Tet(A), tet(K), Tet(M), and Tet(S),
have the potential to reduce the susceptibility or resistance to
minocycline [38–41]. The tet(B) efflux pump, associated with the
major facilitator superfamily, and most commonly spread, is found
in Gram-negative pathogens and confers resistance to tetracycline,
doxycycline and minocycline [39,42–44]. Nevertheless, the ex-
pression of tetB in tetB-positive, tetracycline-resistant multidrug
resistant (MDR) Acinetobacter baumannii strains has been shown to
reduce susceptibility notably or elevate the MICs of minocycline
(from <1 to 8 mg/mL) in European hospitals [45].
Another efflux mechanism, including resistance-nodulation-
division (RND)-type efflux pumps (e.g. AdeFGH, AdeIJK) has also
been proposed for minocycline resistance [43]. Moreover, there is a
direct link between the lack of tetB gene and minocycline
susceptibility [42]. In an experimental study, it was found that
93.3% (154/165) of A. baumannii strains were resistant to
minocycline and harboured the tetB gene [46]. Thus, it was of action and resistance.
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diagnostic gene testing to define minocycline resistance [46].
Alterations in the interdomain loop region of the tetA(A)
tetracycline resistance gene enhance minocycline efflux [47].
Minocycline resistance of the methicillin-resistant Staphylo-
coccus pseudintermedius, which harbours tet(M) and confers
resistance to all three tetracyclines, has been found [42]. The tet
genes encoding ribosomal protection proteins (RPPs) confer a wide
spectrum of antibiotic resistance. The RPPs are cytoplasmic
proteins with GTPase activity, resulting in resistance to both
doxycycline and minocycline [39,48]. A conformational alteration
occurs when the antibiotic molecule attaches to the ribosome. A
Tet(O) protein binds to guanosine-5ʹ-triphosphate (GTP) to form a
Tet(O)-GTP complex. Then, this complex attaches to the ribosome
and continue the antibiotic molecule away. The GTP molecule is
then cleaved to form a Tet(O)–guanosine diphosphate (GDP)
complex; finally, this complex is unattached from the ribosome,
allowing it to return to its standard conformation. On the otherTable 1
International minocycline in vitro susceptibility breakpoints.
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unbinds the antibiotic from the ribosome, and the antibiotic
remains unaffected [39,49,50].
The tetM gene has been found in A. baumannii and encodes an
RPP from tetracycline, doxycycline and minocycline. This gene is a
homologue of the Staphylococcus aureus gene; a genetic horizontal
transfer between bacteria has been proposed [51]. The RPPs are
found in various spectra of bacteria such as Gram-positive,
anaerobic and nonenteric Gram-negative pathogens. Efflux genes
are extensively disseminated and are usually associated with large
plasmids, which frequently harbour other antibiotic resistance
genes [39,52]. Minocycline resistance through tet(S), encoded by a
new, small, low copy number plasmid, has also been found in a
human-derived oral Streptococcus infantis isolate [40]. Previous
studies have demonstrated the presence of plasmid-located tet(S)
in Lactobacillus plantarum CCUG 43738, which proves that
lactobacilli from various sources can harbour acquired antibiotic
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and it has been found to harbour a tet(S) gene found on a plasmid of
14 kb [53]. Vilacoba et al. detected the presence of tet(B) located
on an insertion sequence of an ISCR2 mobile element in all
minocycline-resistant A. baumannii isolates. This genetic platform
of the tet(B) gene confirms a novel mechanism that makes it
possible to spread among A. baumannii isolates [57]. Fig. 2 depicts
the minocycline mechanism of resistance.
6. International in vitro susceptibility breakpoints
Currently, several laboratory methods, including broth micro-
dilution and disk diffusion, have been introduced for the
determination of in vitro susceptibility to tigecycline. Bacteria
that are susceptible to tetracycline are also considered to be
susceptible to doxycycline and minocycline [58,59]. However,
some bacteria defined as intermediate or resistant to tetracycline
might be susceptible to doxycycline, minocycline or both according
to the Clinical and Laboratory Standards Institute (CLSI) and
European Committee on Antimicrobial Susceptibility Testing
(EUCAST) guidelines [58,59]. Because CLSI criteria used to evaluate
tigecycline susceptibility were not available, the tigecycline
international in vitro susceptibility breakpoints in bacteria
according to EUCAST, CLSI [58,59], the FDA [60] and the British
Society for Antimicrobial Chemotherapy (BSAC) [61] are shown in
Table 1.
7. Antibacterial activity
The drugs available to treat MDR A. baumannii are limited, so i.v.
minocycline is a new and valuable repurposing of an old antibiotic
for the intensive treatment of Acinetobacter spp. and other Gram-
positive and Gram-negative pathogens. Minocycline is used for the
treatment of a wide range of diseases, such as acne vulgaris, skin
and soft tissue infections (e.g. Staphylococcus aureus, Actinomyces
spp.), Lyme disease, gastrointestinal infections (e.g. Vibrio cholera,
Campylobacter spp.), sexually transmitted diseases (e.g. Urea-
plasma urealyticum, Chlamydia trachomatis, Klebsiella granuloma-
tis), rickettsial infections (e.g. rickettsial pox, Rocky Mountain
spotted fever), and zoonotic infections (e.g. Brucella spp., Yersinia
pestis, Chlamydia psittaci, Bartonella bacilliformis, Francisella tular-
ensis) [62].
The prevalence of resistance varies across different regions. For
example, in the United States, minocycline resistance is low in the
New England and South Atlantic regions but is high in the Middle
Atlantic and East North Central regions. Tetracycline-resistant
strains show varying degrees of resistance to minocycline and
doxycycline. Minocycline has a low MIC90 at present. Obviously,
the more this drug is prescribed, the greater the chance of
developing resistance [63].
7.1. Minocycline resistance in A. baumannii
The use of minocycline in the treatment of MDR Gram-negative
bacterial infections has been increasing. Many studies have
focused on the A. baumannii infections. For the MDR A. baumannii
organism (MDRO), minocycline is the second most active agent in
vitro and might be the only therapeutic option in certain cases.
Minocycline could also be used to treat other MDRO Gram-
negative infections [64,65]. The Tigecycline Evaluation and
Surveillance Trial (TEST) study reported the highest global
minocycline susceptibility rate (84.5%) between 2004 and 2013
[13]. However, there are no randomized controlled experiments,
and in vivo data are limited. Otherwise, minocycline has
consistently shown favourable results for oral and intravenous
treatment. In a systematic review of clinical evidence by Fragkouet al. [66], the role of minocycline was highlighted in the treatment
of nosocomial infections caused by MDR, extensively drug-
resistant (XDR) and pandrug-resistant A. baumannii. A favourable
clinical and microbiological success rate of minocycline activity
was shown in A. baumannii isolates.
The role of oral minocycline in the treatment of wound
infections was found by Griffith et al. [67]; seven of eight cases
with MDR A. baumannii soft tissue infections were clinically
treated 4–6 weeks after the use of minocycline alone or in
combination with another antibiotic
In Argentina, Vilacoba et al. have reported that the emergence
of minocycline resistance in A. baumannii reaches 40% of isolates in
different centres [68] and, in Iran, 17% of A. baumannii hospital
isolates exhibited resistance to minocycline [69]. The tet(A) is the
bacterial tetracycline resistance gene and generally confers
resistance to tetracycline alone, whereas tet(B) confers resistance
to tetracycline and minocycline [45]; therefore, if an organism has
an elevated MIC to tetracycline, the tetA or tetB genes do not
necessarily cause resistance to minocycline. In the study conducted
by Lomovskaya et al. in 2018, 258 A. baumannii strains were used to
define MIC frequency dispensations for the tetB-positive and tetB-
negative sets of strains. Among them, 93 tetB-negative strains
showed a minocycline MIC  4 mg/mL. Among 165 tetB-positive
strains, 154 had a minocycline MIC > 4 mg/mL [70].
In A. baumannii, efflux pumps are effective for transporting out
tetracycline and doxycycline. Lomoskaya et al. [70] confirmed that
only 11 of 165 isolates (6.7%) were TetB-positive and susceptible to
minocycline, whereas 93 of 93 strains were minocycline-suscepti-
ble and TetB-negative. Therefore, the presence of TetB can be an
important reason for sensitivity to minocycline [46]. It is
noteworthy that sensitivity to minocycline is not associated with
the presence of the RND pumps, so tigecycline-resistant A.
baumannii can remain susceptible to minocycline [37].
Carbapenems have been identified as suitable agents for the
treatment of MDR A. baumannii infections but carbapenem-
resistant A. baumannii (CRAB) has rapidly increased in frequency.
CRAB accounts for 65% of A. baumannii pneumonia cases in Europe
and the United States, whereas more than 60% of isolates in Asia
have been found to be both pandrug and carbapenem-resistant
[71]. Minocycline can overcome many mechanisms of tigecycline
resistance in A. baumannii. Furthermore, minocycline has favour-
able pharmacokinetic and pharmacodynamic properties, and
excellent in vitro activity against drug-resistant A. baumannii.
The Eurofins Surveillance Network reported that resistance to
minocycline decreased from 56.5% in 2003–2005 to 30.5% in 2009–
2012 [72].
7.2. Minocycline resistance in Enterobacteriaceae
Minocycline susceptibility in carbapenemase-producing carba-
penem-resistant Enterobacteriaceae such as Escherichia coli
(48.5%) and Klebsiella pneumoniae (3.3%) were reported by
Yamamoto in 2017 [73]. The level of resistance to minocycline
in Gram-negative pathogens varies from 4.2% for A. baumannii to
30.3% for extended-spectrum β-lactamase (ESBL)–positive K.
pneumoniae. In ESBL-positive isolates of E. coli, K. pneumoniae
and Klebsiella oxytoca, resistance to minocycline is at least twofold
higher in comparison with all isolates of each species. For example,
minocycline-resistant E. coli isolates are 11.2%, and 25.1% of ESBL-
positive isolates of E. coli exhibit resistance to minocycline.
Minocycline-resistance is common in Gram-negative pathogens,
but rates of cross-resistance to tigecycline are typically very low,
ranging from 0.01% for E. coli to 1% in Enterobacter cloacae [74].
Cha from South Korea indicated that among 85 salmonella
strains, 67 strains were resistant to nalidixic acid, and 41 strains
were resistant to sulfisoxazole. Additionally, 31 and 30 strains were
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does not set breakpoints for Enterobacteriaceae, and there are
limited data on the use of minocycline in Enterobacteriaceae. The
TEST study reported that 71.4% of K. pneumoniae isolates are
globally susceptible to minocycline, but this rate decreases to
52.2% in isolates resistant to carbapenems. It is worthy of note that
the susceptibility of K. pneumoniae to minocycline has gradually
declined between 2004 and 2011, but then a 22.9% increase in
minocycline susceptibility occurred between 2011 and 2013 [76].
According to the study of DiPersio et al., 85% of MDR Serratia
marcescens (N = 20) were resistant to minocycline. MDR E. cloacae
(N = 126) resistance rates against minocycline were the highest
(81.0%), and 75% of MDR Enterobacter aerogenes (N = 24) were
minocycline-resistant [77].
Bartha has shown that the presence of tetX in E. coli
dramatically increases the MIC values of different tetracycline
derivatives, including minocycline [78]. In Gram-negative bacteria,
resistance to tetracycline, doxycycline and minocycline is con-
ferred by the tet(B) gene. RPPs displace tetracycline from the 30S
ribosomal subunit via GTP, depending on attachment to the
ribosomal binding site. In the study by Zeng et al., the U.
urealyticum and Mycoplasma hominis displayed low resistance
rates to josamycin, doxycycline and minocycline (<10%) in both
symptomatic and asymptomatic groups [79]. Horiki et al. evaluat-
ed resistance of Helicobacter pylori to minocycline. They found that
resistance to minocycline was quite as low as amoxicillin (0.06%).
Minocycline could constitute the next candidate drug for third-line
therapy in Japan [80].
7.3. Minocycline resistance in Gram-positive bacteria
Minocycline-resistance in Gram-positive pathogens has a
difference in range, from 0.6% for S. aureus to 22.5% for Enterococcus
faecalis. Minocycline resistance is slightly higher in isolates of
methicillin-resistant S. aureus (MRSA; 1.3%). Stenotrophomonas
maltophilia is naturally resistant to carbapenems, thus, the optimal
treatment for S. maltophilia infection in clinical practice is usually
minocycline, cotrimoxazole, levofloxacin or combination therapy
[81]. Ullah [82] indicated that 60 of 130 clinical isolates of S. aureus
were MRSA, whereas 70 isolates (54.0%) were methicillin-
susceptible S. aureus (MSSA). Seventy-four strains (56.9%) were
resistant to tetracycline (TET-R), 30 strains (23.1%) were resistant
to minocycline and 23 strains (17.7%) were resistant to doxycycline
[82].
Antibiotic resistance is a global problem in regard to
Propionibacterium. Generally, there is high-level resistance to
trimethoprim–sulfamethoxazole (TMP-SMX), clindamycin and
macrolides, whereas resistance to tetracyclines and levofloxacin
has a low potential. Minocycline is reliably effective when
doxycycline or TMP-SMX fails to treat uncomplicated cutaneous
abscesses due to community-associated MRSA [83]. A single G-C
transition mutation in 16S rRNA of the small ribosomal subunit in
Propionibacterium acnes is associated with minocycline resistance.
There is also an association between resistance to tetracycline and
doxycycline. Luk [84] indicated that 47 strains (54.7%) of the 86 P.
acnes were found to be resistant to at least one antibiotic. Eighteen
(20.9%), 14 (16.3%), 14 (16.3%), 46 (53.5%) and 14 (16.3%) of strains
were resistant to erythromycin, tetracycline, doxycycline, clinda-
mycin and minocycline, respectively [84,85]. One criterion to
explain the link between antibiotic resistance and response is
based on the type of antibiotic used, topical or systemic. The MICs
of resistant strains are 2–16 mg/L for minocycline and 4–64 mg/L
for tetracycline, thereby overlapping with plasma levels. Hence,
the concentration in the follicles might be sufficient to inhibit the
resistant strains. Although minocycline has the highest lip-
ophilicity among other cyclines, the partition in the skin sebumseems to be insufficient to inhibit some resistant isolates [86].
Low-dose administration of IR tetracyclines, such as lymecycline
150 mg/daily or minocycline 50 mg/daily, is not subtherapeutic
and can increase the risk of resistance [87]. In Gram-positive cocci,
efflux proteins confer resistance to tetracyclines, but not minocy-
cline [16]. The initial reports of resistance originate from the
United States, with one of the highest minocycline MICs reported
(8–16 mg/mL); however, there are little data available [88].
In acne treatment, the highest resistance to minocycline is
observed respectively in Hong Kong, Singapore, Egypt, India and
Colombia [89]. In a study by Boswihi et al., 143 group B
streptococcus (GBS) isolates, collected from mothers in Kuwait,
were resistant to minocycline (89.5%) [90]. The minocycline-
resistant isolates contained tetM (94.5%), tetL (1.6%), tetO (3.9%) and
tetK (0.8%) [90]. Ciric et al. showed that minocycline resistance is
encoded by tet(S) on a novel small, low copy number plasmid in an
oral S. infantis isolate [40].
The tet(K) gene protects bacteria from tetracycline by a
resistance mechanism known as tetracycline efflux. This mecha-
nism prevents the accumulation of tetracycline in the bacterial cell
[91]. According to Huys et al., high-level resistance to both
minocycline and tetracycline suggests the involvement of an
acquired ribosomal protection mechanism [91]. In Gram-positive
bacteria, tet genes tet(M), tet(O), tet(Q), tet(S) and tet(W) are the
most commonly detected ribosomal protection. It has been
determined that tetracycline resistance in L. plantarum has so
far been associated with the presence of only the tet(M) gene [56].
Minocycline monotherapy should be avoided to prevent the
development of resistant strains. Furthermore, cross-resistance or
cross-susceptibility is found in a limited number of isolates,
indicating that tetracycline should not be used as a predictive
determinant for susceptibility or resistance to minocycline.
Susceptibility to minocycline should be assessed routinely by
the laboratory according to CLSI criteria. Moreover, the use of
minocycline alone or in combination needs to be guided by the
results of clinical trials and further laboratory studies [92].
7.4. Minocycline activity in combination with other drugs
In recent years, the use of minocycline with other compounds
and its beneficial effects have been considered in various studies.
MDR A. baumannii is currently a major cause of respiratory
infections in intensive care unit patients [93]. Combination therapy
with minocycline, tigecycline, polymyxins, carbapenems and
daptomycin is a common treatment strategy for MDR A. baumannii
[94]. The results of these studies show that polymyxin B would
break apart the cell membrane, exert a suitable functioning of the
efflux pumps and thereby enhance the activity of minocycline [95].
One study mentioned mortality in the range of 30.8–58.3% in A.
baumannii bacteraemia. This rate is dependent on the antimicro-
bial combination used [96]. In the study by Bowers et al.,
minocycline and polymyxin B were checked out for pandrug-
resistant A. baumannii, and they found that the MIC of each drug
decreased with the combination of polymyxin B and minocycline
[97]. Research studies have indicated that combinations such as
colistin–minocycline, colistin–rifampicin and colistin–merope-
nem are synergistic against XDR A. baumannii strains in vitro.
When colistin is unavailable, the minocycline–meropenem com-
bination might be an alternative option for the treatment of
infections caused by XDR A. baumannii [98].
Periodontitis (gum disease) is an infectious disease that
damages the soft tissue and destroys the bone that supports
teeth; periodontitis leads to tooth loss. Minocycline is widely used
for the treatment of periodontitis [99]. Minocycline promotes
periodontal tissue regeneration and has a wide antibacterial
spectrum. The combination of minocycline and metronidazole can
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tissues, enhance the antibacterial effect and reduce the level of
cytokines in gingival crevicular fluid in the process of periodontitis
treatment [100].
Acne vulgaris is a common chronic skin disease involving
blockage and/or inflammation of pilosebaceous units [101].
Minocycline is an effective treatment for moderate to moderately
severe inflammatory acne vulgaris. Compared with minocycline
alone, the combination of photodynamic therapy (PDT) with
minocycline significantly improves clinical efficacy in patients
with moderate to severe facial acne [102].
Combination therapy can be used for the treatment of
antifungal-resistant fungi. Fluconazole with minocycline can work
synergistically against fluconazole-resistant Candida albicans.
Their mechanism of action suggests that minocycline causes
fluconazole to penetrate the biofilm better and leads to intracellu-
lar calcium release instead of affecting the uptake and efflux of
fluconazole [103]. Klebsiella pneumoniae carbapenamase (KPC)-
producing K. pneumoniae is not only resistant to β-lactams, but also
shows reduced susceptibility to other antimicrobial classes
especially used in clinical practice. Studies have shown that the
combination of minocycline with aminoglycoside exerts a strong
synergistic and bactericidal impact in susceptible isolates for
infections caused by KPC-producing K. pneumonia and can
effectively prevent the emergence of resistant mutants [104].
KPC-producing K. pneumoniae usually causes serious infections in
immunocompromised patients, so the treatment should be timely
and efficacious [104]. Worldwide reports of minocycline resistance
rates in different pathogens are shown in Table 2.
8. Minocycline effectiveness in clinical trials
Minocycline is an effective antibiotic against various infections
of the skin (especially severe acne), urinary and respiratory tracts,Table 2
Prevalence of minocycline resistance worldwide.
Study, year Location Method Bacteria 
Luk et al. (2013) [84] Hong Kong AD Propionibacte
Tan et al. (2007) [134] Singapore MBD P. acnes 
Moon et al. (2012) [135] Korea DD P. acnes 
Mendoza et al. (2013) [136] Colombia AD P. acnes 
Sardana et al. (2015)
[89]
India AD P. acnes 
Ross et al. (2001) [137] USA AD P. acnes 
Luk et al. (2013) [84] Hong Kong AD P. acnes 
Gonzalez et al. (2010) [138] USA Etest P. acnes 
Nakase et al. (2014) [139] Japan AD P. acnes 
Ishida et al. (2008) [140] Japan AD P. acnes 
Mendoza et al. (2013) [136] Tokyo AD P. acnes 
Song et al. (2011) [141] Korea Etest P. acnes 
Ullah et al. (2012) [82] Pakistan AD Staphylococcu
Ullah et al. (2012) [82] Pakistan AD MRSA 
Vilacoba et al. (2015) [68] Argentina DD Acinetobacter 
Mohajeri et al. (2013) [69] Iran DD A. baumannii 
Lomovskaya et al. (2018) [70] United States MBD A. baumannii 
Cha et al. (2013) [75] South Korea DD Salmonella 
DiPersio et al. (2007) [77] United States MBD Multidrug-res
Wang et al. (2014) [142] China DD U. urealyticum
M. hominis
Horiki et al. (2009)
[80]
Japan DD H. pylori 
AD, agar dilution; BMD, broth microdilution; DD, disk diffusion; KPC, Klebsiella pneumonia
NA, not available.and genital system (gonorrhoea, syphilis, chlamydia, mycoplasma).
It is also used as a second-line drug in infections in patients with a
penicillin treatment allergy. Owing to the side effects following the
systemic administration of minocycline, its use in such infections
has been limited and is now more common for the treatment of
acne vulgaris. Recently, many studies have focused on the
interesting anti-inflammatory and neuroprotective efficacy of
minocycline, a topic that was first mentioned in 2007 in case
reports [3]. In this review, we surveyed 40 clinical trials that
investigated the effect of minocycline on various diseases. About
one-third of the studies (13 cases) were conducted in the United
States. India and Canada had five investigations. Iran, Japan and
Brazil each has three studies, ranked in third position among
others.
Several studies have investigated the effect of minocycline on
schizophrenia. Wehring et al. surveyed the effect of adjunctive
minocycline to clozapine (an antipsychotic drug) in patients with
schizophrenia in 2018 [105]. After 10 weeks of treatment, it was
found that the administration of minocycline could increase the
clozapine plasma level and be effective in those with schizophre-
nia. In another study, the beneficial effect of minocycline on
negative symptoms such as social withdrawal, emotional blunting
and apathy, which are unaffected by common antipsychotic drugs
in early schizophrenia, was investigated. The authors studied the
efficacy of minocycline treatment for 1 year in early psychosis to
improve negative symptoms in 144 participants compared with
placebo given in Brazil and Pakistan. It was found that minocycline
could mainly reduce negative symptoms in the early course of the
schizophrenia [106].
Many studies have investigated the effect of minocycline on
various mental disorders, including depression. Savitz et al., in
2018, showed that treatment of bipolar depression with adjuvant
therapy of minocycline and aspirin might be an efficacious strategy











49 0 MIC50 = 0.5MIC
90 = 2
69 0 MIC90 = 0.5
48 0 MIC90 = 0.5
69 0 MIC90 = 0.5
31 MIC50 = 0.065MIC
90 = 0.125
s aureus 130 23.08 MIC50 = 2MIC
90 = 64
60 50 MIC50 = 8MIC
90 = 64
baumannii 77 40 –
104 16.3 –
258 59.6 MICs > 4
85 35.2 –








e carbapenemase; MDR, multidrug-resistant; MRSA, methicillin-resistant S. aureus;
Table 3
Data from clinical trials of minocycline against various diseases.







Peri-implantitis 50 Local delivery of minocycline combined
with surgical treatment provides
significant benefits in terms of clinical
parameters and radiographic bone fill, with




Minocycline ointment 4 weeks Japan Chronic
periodontitis
30 Although local administration of
minocycline may slightly help improve
clinical, microbiological and crevicular
cytokine levels in periodontal pockets, a








60 Significant reduction in clinical parameters
with improvement in periodontal status on
application of minocycline ointment, as an







1 week Brazil Apical
periodontitis
48 Significantly improved root canal
disinfection; effects were at least












Minocycline microgranules adjunct to
scaling and root planning resulted in
greater reduction of BOP and PD, higher
CAL gain, increased probability of Pg
suppression and retarded recolonization of







Periodontitis 748 SRP plus minocycline more effective than
SRP alone
Ho et al. (2011)
[119]




HIV 7 No discernible effects of minocycline on
CSF, blood HIV-1 RNA, or biomarkers of
immune activation and inflammation; this
pilot study of biological responses to
minocycline suggests little potential for its
use as an adjunctive antiviral or






100 mg twice daily 6 weeks Iran HIV 46 HIV patients Significantly greater and more rapid
improvement in depressive symptoms of
HIV-AIDS patients receiving 100 mg




100 mg of minocycline or matching





HIV 73 participants Minocycline was safe and well tolerated in
HIV-positive individuals; however, it did













107 Minocycline was safe and well tolerated in
individuals with HIV-associated cognitive










5 Minocycline as primary treatment was
associated with improved visual function,
central macular oedema and vascular
leakage, comparing favourably with
historical controls from previous studies
Syngle et al.
(2014) [113]
100 mg 6 weeks India Type 2 diabetes
mellitus (T2DM)
50 6-week oral treatment with minocycline
was safe, well tolerated and significantly
improved peripheral and autonomic
neuropathy in type 2 diabetic patients






Taiwan Type 2 diabetes
mellitus (T2DM)
28 Nonsurgical periodontal therapy with or
without subgingival minocycline
application may achieve significant
periodontal improvement and moderate
improvement in HbA1c, but had no
significant effect on plasma levels of IL-6,
CRP, or sRAGE in patients with poorly
controlled T2DM. For patients with both
periodontal disease and diabetes,
nonsurgical periodontal treatments might





USA Acne vulgaris 961 Significantly reduced both inflammatory
and noninflammatory lesions in patients
with moderate to severe acne
Dreno et al.
(2001) [131]
100 mg minocycline Over 3
months
France Acne vulgaris 332 Minocycline and zinc gluconate are both
effective in the treatment of inflammatory
acne, but minocycline has a superior effect,
evaluated as 17% in our study
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Table 3 (Continued)
Study (year) Dosage, mg/day, route Duration Country Disease No. of patients Outcome
Wehring et al.
(2018) [105]
50-mg capsule twice daily for 1 week,
increased to 100 mg capsule twice
daily for the remainder of the study
10
weeks
USA Schizophrenia 52 Increase in clozapine plasma levels after
the initiation of minocycline compared







Schizophrenia 144 (94 completed) The addition of minocycline to TAU early in











114 25% improvement in TFC. The results





200 mg of oral minocycline 5 days Iran Ischaemic stroke 60 Patients with ischaemic stroke who
received oral minocycline daily for 5 days
had significantly better neurological
outcomes on day 90 than controls
Srivastava et al.
(2012) [146]
Oral minocycline 200 mg/day 5 days India Acute ischaemic
stroke
50 Patients with acute ischaemic stroke had
significantly better outcome with
minocycline treatment compared with
those given placebo; minocycline could be










20 AUC comparisons for several individual
symptoms and symptom interference
favoured minocycline but were not
statistically significant; The greatest
numerical differences occurred for
systemic symptoms, larger towards








Canada Multiple sclerosis 142 The risk of conversion from a clinically
isolated syndrome to multiple sclerosis
was significantly lower with minocycline




Patients weighing up to 25 kg, 25 mg
once daily; those weighing between
25 and 45 kg, 50 mg once daily; those







55 Minocycline treatment for 3 months in
children with FXS resulted in greater global
improvement than placebo; treatment for
3 months appears safe, however, longer
trials are indicated to further assess
benefits, side effects, and factors associated
with a clinical response to minocycline
Paribello et al.
(2010) [124]
100 or 200 mg of minocycline daily,
oral
8 weeks Canada FXS 20 Minocycline provides significant functional








281 A trend towards better outcomes was
observed with minocycline, especially in




3 mg/kg daily 8 weeks USA Angelman
syndrome (AS)
25 Clinical and neuropsychological measures
suggested that minocycline was well
tolerated and caused improvements in the





3 mg/kg/day, twice daily orally 16
weeks
Spain AS 32 Minocycline treatment for up to 16 weeks
in children and young adults with AS
resulted in lack of significant
improvements in development indices
compared with placebo treatment;




100 mg bid 6 weeks United
States
Bipolar depression 99 Aspirin and minocycline might be








71 adults The primary outcome was not significant,
but improvements in other comprehensive
clinical measures suggested that
minocycline might be a useful adjunct to
improve global experience, functioning





Minocycline capsules, 200 mg initially,
then 100 mg every 12 h until surgery,
or placebo.
— Iran Acute kidney injury
(AKI) after cardiac
surgery
38 Minocycline did not protect against AKI
post-CABG
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Table 3 (Continued)
Study (year) Dosage, mg/day, route Duration Country Disease No. of patients Outcome
Casha et al.
(2012) [129]
Minocycline 200 mg i.v. twice daily 7 days Canada Spinal cord injury 52 Functional outcomes exhibited differences
that lacked statistical significance but that
might be suggestive of improvement in
patients receiving the study drug. The
minocycline regimen established in this
study proved feasible and safe and was
associated with a tendency towards





Minocycline 100 mg once daily 14 days Belgium Neuropathic
lumbar radicular
pain
60 Not likely to be clinically meaningful
Fouda et al.
(2017) [151]
400 mg minocycline i.v., followed by
400 mg minocycline oral daily
4 days Canada Acute cerebral
haemorrhage
16 In intracerebral haemorrhage, a 400-mg











11 No serious adverse effects due to
minocycline were observed; demonstrated
the efficacy and safety of minocycline in
recent-onset NFI in leprosy patients
Campos et al.
(2011) [126]
Minocycline with EDTA solution
(CATH-SAFE1 , 3 mg/mL of
minocycline and 30 mg/mL of EDTA)





was significantly higher in the
minocycline-EDTA group than in the
heparin group (P = 0.005); in conclusion, a
minocycline-EDTA catheter lock solution
was effective in the prevention of catheter-











The silver-platinum-carbon (SPC) catheter
was a clinically effective antimicrobial
catheter; however, the rifampicin-
minocycline (RM) catheter had a lower
colonization rate: SPC-impregnated
catheters with RM-coated catheters.











129 patients The use of antibiotic-impregnated
catheters was associated with extremely
low risk of CSF infection compared to the
reported mean of nearly 9% for standard
EVD catheters. Infection rates for both C/R
and M/R EVD catheters were 0. These
results support the use of antibiotic-
impregnated EVD catheters in routine
clinical practice—minocycline-rifampin









50 Minocycline showed good in vitro activity
against MRMP and shortened the duration
of fever in paediatric patients infected with
MRMP compared with the duration of fever
in patients treated with macrolides
Kawai et al.
(2013) [128]
4 mg/kg twice daily 14 days Japan M. pneumoniae
pneumonia (MRM)
188 children Clinical and bacteriological efficacy of
macrolides against MRM was low
Minocycline rather than tosufloxacin could
be considered the first-choice drug for








Autism 11 children Minocycline might have effects in the CNS
by modulating the production of
neurotrophic growth factors. However, in
this small group of children, no clinical
improvements were observed during or
after the 6 months of minocycline
administration
AUC, area under the curve; BOP, bleeding on probing; CAL, clinical attachment level; CRP, C-reactive protein; CSF, cerebrospinal fluid; HbA1c, haemoglobin A1c; IL-6,
interleukin 6; PD, pocket depth; PDT, photodynamic therapy; Pg, Porphyromonas gingivalis; sRAGE, Soluble receptor for AGE; SRP, scaling and root planing; TAU, treatment as
usual; Td, Treponema denticola; TFC, Functional capacity.
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(AS) [108]. Although minocycline treatment for AS patients did not
result in significant improvements, treatment with this antibiotic
seemed to be safe and well tolerated. Grieco et al. in 2014 found
that minocycline in children with AS was well tolerated and caused
improvements in their adaptive behaviours. They also suggestedthat further investigation of its optimal dosage and efficacy of long-
term use in AS patients was warranted [109].
Minocycline’s efficacy was also investigated in acute encepha-
litis syndrome, in which a trend towards better outcomes of
treatment with minocycline was observed, especially in patients
who survived the initial stay in hospital [110]. Moreover, the role of
A. Asadi et al. / Journal of Global Antimicrobial Resistance 22 (2020) 161–174 171minocycline in patients with Huntington disease (HD), a fatal
neurotic disorder, has been studied. This study was the first trial in
HD patients suggesting that minocycline treatment is not futile.
Minocycline is a tetracycline that inhibits the release of
apoptogenic and reactive microgliosis, important factors in the
induction of HD. Minocycline slows the functional decline in HD
patients by at least 25%, and this finding was accepted (P = 0.12)
[111].
Some trials have focused on the effectiveness of minocycline in
diabetic patients. For example, in one study, oral minocycline
improved visual function, central macular oedema and vascular
leakage in patients with diabetic macular oedema (DME)
compared with controls [112]. Syngle et al., in 2014, indicated
that the oral administration of minocycline for 6 weeks was safe
and significantly improved peripheral and autonomic neuropathy
in type 2 diabetic patients [113]. In a randomized controlled clinical
trial by Lin et al. in 2012, it was revealed that minocycline
treatment might be helpful in diabetic control for patients with
both periodontal disease and diabetes [114].
Some clinical trials have investigated the efficacy of minocy-
cline in periodontitis. Minocycline in a triple antibiotic solution
significantly improved root canal disinfection compared with
calcium hydroxide with chlorhexidine in patients with apical
periodontitis, such as calcium hydroxide–chlorhexidine paste.
Because of the easy delivery and efficacy of minocycline solution, it
can be used as an appropriate disinfecting medicament for
conventional non-surgical endodontic problems [115]. In a
randomized clinical and microbiological trial performed by
Chiappe et al., minocycline microgranules were subgingivally
applied to subjects with chronic periodontitis [116]. This study
showed that minocycline microgranules as an adjunct to scaling
and root planing resulted in a greater reduction of bleeding on
probing (BOP) and pocket depth (PD), higher clinical attachment
level (CAL) gain, increased probability of Porphyromonas gingivalis
(Pg) suppression and retarded recolonization of Treponema
denticola (Td) than root instrumentation alone [116].
Minocycline has also been used as an ointment in the treatment
of generalized chronic periodontitis and has shown significant
reduction in various parameters such as gingival bleeding index,
probing PD and gain in CAL in comparison with the control group.
This ointment has also significantly reduced the plaque index and
clinical parameters when used as an adjunct treatment to
periodontal flap surgery in generalized chronic periodontitis [117].
There are several clinical trials investigating minocycline’s
effect on human immunodeficiency virus (HIV) infection and its
complications. In one study, the antidepressant effect of
minocycline was investigated in 46 HIV patients who suffered
mild to moderate depression. They observed that the adminis-
tration of 100 mg minocycline orally twice a day was safe and
effective in improving depressive symptoms [118]. In a study by
Ho et al., although minocycline was not able to modulate the HIV
infection of CSF or immune activation in chronic untreated HIV-
1 infection, it might have the potential to be used as an
adjunctive antiviral or immunomodulating therapy in patients
with chronic HIV infection [119]. In two other trials, it has been
observed that despite not improving HIV-associated cognitive
impairment by minocycline treatment, it was safe and well
tolerated [120,121].
A few studies have surveyed the effect of minocycline on other
diseases. In one study, minocycline was used in patients with
recent-onset leprosy and clinical nerve function impairment (NFI).
This study demonstrated minocycline treatment as an effective
and safe approach in patients, without causing any serious adverse
effect [122].
Minocycline has even been tested for the treatment of multiple
sclerosis. Metz et al., demonstrated that minocycline reduced therisk of conversion from a first demyelinating event (clinically
isolated syndrome) to multiple sclerosis compared with placebo
treatment over 6 months [123].
Paribello et al. launched a trial on the treatment of fragile X
syndrome (FXS, a genetic disorder that causes learning disabilities
and cognitive impairment) by minocycline. This study showed that
minocycline was well tolerated, providing significant functional
benefits in FXS patients [124]. In another similar study in 2013,
Leigh et al. surveyed the efficacy of minocycline in the treatment of
FXS children and adolescents for 3 months. The results proved the
safety of minocycline treatment for FXS, and this antibiotic could
help relieve FXS. However, the researchers declared that longer
trials were needed to assess the benefits, side effects and other
aspects of this therapy further [125].
In another interesting study, minocycline was used in
combination with EDTA solution to prevent bacteraemia in
haemodialysis patients. This mixed solution significantly helped
prevent catheter-related bacteraemia in patients (P = 0.005) [126].
Oral minocycline as an adjunct to aspirin administered daily in
patients with ischaemic stroke for 5 days had significantly better
neurological outcomes on day 90 than in controls [127]. One of the
newer antibacterial effects of minocycline was surveyed against
macrolide-resistant Mycoplasma pneumoniae in paediatric patients
[128]. Results indicated that minocycline, rather than ofloxacin,
could be considered as the first-choice drug for the treatment of M.
pneumoniae in children older than 8 years [128]. Cash et al. in 2012
used minocycline for the treatment of acute spinal cord injury.
Their trial proved minocycline treatment as safe and feasible, and
they declared that it could even improve several outcome
measures in acute spinal cord injury patients (but not significantly)
[129].
Acne vulgaris is one of the most important diseases to be
treated by minocycline, and many trials have reported the
beneficial effects of this antibiotic in this regard [130,131]. In
some studies, minocycline has been used in catheters. Result of
these studies show that minocycline is capable of being one of the
most efficacious materials used as an antimicrobial agent in
catheters [126,132,133]. Table 3 depicts the clinical trials of
minocycline against various diseases.
9. Conclusions
Minocycline is a wide-spectrum antibiotic and is active against
MDR Gram-positive and Gram-negative bacterial infections.
Minocycline’s mechanism of action is to bind to the bacterial
30S ribosomal subunit and inhibit protein synthesis, as do other
tetracyclines. Owing to the side effects following the systemic
administration of minocycline, its use in such bacterial infections
has been limited. It has been approved for the treatment of acne
vulgaris, some sexually transmitted diseases and rheumatoid
arthritis. However, there are limited data regarding the preva-
lence, mechanism of resistance and clinical effectiveness of
minocycline.
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